Court denies Sun Pharma’s bid to avoid trial
25-11-2021
Jazz sues Avadel over Xyrem patent
16-11-2021
Jazz Pharmaceuticals acquires UK medical cannabis firm for $7.2bn
04-02-2021
Michael Vi / Shutterstock.com
Molina Healthcare claims that Jazz Pharmaceuticals delayed generics of its flagship narcolepsy drug Xyrem (sodium oxybate) and hiked the drug prices to increase profits when it was on the verge of bankruptcy.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Antitrust, generics, ANDA, Lupin, Hikma, Jazz Pharmaceuticals, Xyrem
